B. Riley Wealth Advisors Inc. Sells 2,586 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

B. Riley Wealth Advisors Inc. reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 8.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,370 shares of the medical research company’s stock after selling 2,586 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $14,537,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TMO. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $2,909,524,000. International Assets Investment Management LLC lifted its stake in shares of Thermo Fisher Scientific by 61,995.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock valued at $535,923,000 after purchasing an additional 1,008,045 shares during the period. Veritas Asset Management LLP lifted its stake in shares of Thermo Fisher Scientific by 70.1% in the 4th quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company’s stock valued at $898,175,000 after purchasing an additional 697,383 shares during the period. Winslow Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $333,786,000. Finally, Clearbridge Investments LLC lifted its stake in shares of Thermo Fisher Scientific by 33.1% in the 4th quarter. Clearbridge Investments LLC now owns 2,228,730 shares of the medical research company’s stock valued at $1,182,987,000 after purchasing an additional 553,695 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $4.05 during trading hours on Monday, hitting $568.00. The company’s stock had a trading volume of 1,278,122 shares, compared to its average volume of 1,486,867. The business has a 50 day moving average price of $575.16 and a two-hundred day moving average price of $558.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a market cap of $216.82 billion, a PE ratio of 36.69, a PEG ratio of 2.67 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Analysts expect that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Deutsche Bank Aktiengesellschaft lifted their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. HSBC lifted their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Citigroup assumed coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Finally, The Goldman Sachs Group lifted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $607.94.

Check Out Our Latest Analysis on TMO

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold a total of 22,000 shares of company stock valued at $12,532,780 over the last quarter. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.